½ÃÀ庸°í¼­
»óǰÄÚµå
1451561

¼¼°èÀÇ ÀÓ»ó ¿µ¾ç ½ÃÀå º¸°í¼­ : Á¦Ç°, Åõ¿© °æ·Î, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°(2024-2032³â)

Clinical Nutrition Market Report by Product, Route of Administration, Application, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 147 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ÀÓ»ó ¿µ¾ç ½ÃÀå ±Ô¸ð´Â 2023³â 519¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº 2024³âºÎÅÍ 2032³â±îÁö 7.5%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸À̸ç 2032³â±îÁö 1,010¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ÀÓ»ó ¿µ¾çÀº ÀǷ῵¾ç¿ä¹ýÀ» ÅëÇØ Áúº´À» °ü¸®ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃá ¿µ¾ç°úÇÐÀÇ ÇÑ Àü¹®ºÐ¾ß¸¦ ¸»ÇÕ´Ï´Ù. ¶ÇÇÑ Çʼö ¿µ¾ç¼Ò ºÎÁ·À¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¸¸¼º Áúȯ°ú °ü·ÃµÈ ¿µ¾ç ¹× ´ë»ç »óÅÂÀÇ Áø´Ü ¹× ¿¹¹æµµ Æ÷ÇÔÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î ÀÌ¿ë °¡´ÉÇÑ ÀÓ»ó ¿µ¾çÀÇ À¯Çü¿¡´Â ¿µ¾Æ ¿µ¾ç, °æÀå ¿µ¾ç, ºñ°æ±¸ ¿µ¾ç µîÀÌ ÀÖ½À´Ï´Ù. ÀÓ»ó ¿µ¾çÀº ¿µ¾ç °áÇÌÀÇ °á°ú °¨¼Ò, Áúº´ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ °­È­, ¸é¿ª ¼öÁØ Çâ»ó, ¼·Ãë ´É·Â °­È­ µî ´Ù¾çÇÑ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù.

ÀÓ»ó ¿µ¾ç ½ÃÀå µ¿Çâ :

ºñ¸¸, °íÇ÷¾Ð, ºñÁ¤»óÀûÀÎ ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡¿Í °°Àº À§ÇèÀ» Áõ°¡½ÃŰ´Â ´ë»ç Àå¾ÖÀÇ À¯º´·ü Áõ°¡´Â ÁÖ·Î ¼¼°è ÀÓ»ó ¿µ¾ç ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼º À§Àå Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡´Â ÀçÅÃÄ¡·á ¸ðµ¨¿¡¼­ ÀÓ»ó ¿µ¾ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡ Á¶»ê¾Æ Ãâ»ê Áõ°¡¿Í ¼Ò¾Æ°ú ÀÇ·á ºÐ¾ß¿¡¼­ ÀÓ»ó ¿µ¾ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶óÀÇ Áö¼ÓÀûÀÎ ¾÷±×·¹À̵å¿Í Áúº´ °ü¸®¸¦ À§ÇÑ ÀÓ»ó ¿µ¾ç ÀýÂ÷¿¡ ´ëÇÑ ½¬¿î Á¢±Ù¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥ µµÀÔÀº Áß¿äÇÑ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, Äڷγª19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ Äڷγª ¹ÙÀÌ·¯½º °¨¿° À§ÇèÀ» ¿¹¹æÇϱâ À§ÇØ ÀÓ»ó ¿µ¾çÀ» Æ÷ÇÔÇÑ ¸é¿ª·Â °­È­ ´ëüǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °¨¿°À¸·Î ÀÎÇØ ½ÉÇÑ ½Ä¿åºÎÁø, ¹«Èİ¢¼º ¹Ì°¢ Àå¾Ö, ¼³»ç µîÀÌ ¹ß»ýÇÏ¿© Áúº´°ú °ü·ÃµÈ ¿µ¾ç½ÇÁ¶¸¦ À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó ¿µ¾çÀº Äڷγª19 ȯÀÚÀÇ ¸é¿ª ¹æ¾î·Â Çâ»ó°ú ÇÔ²² ±Þ¼º ¿µ¾ç½ÇÁ¶¿Í ´Ü¹éÁú °áÇÌÀ» Ä¡·áÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁöÁú ¿¡¸ÖÁ¯ÀÇ ÃÖÀûÈ­, ¾×ü ÇüÅÂÀÇ °æ±¸¿ë ÀÓ»ó ¿µ¾çÁ¦ ó¹æ µµÀÔ°ú °°Àº ÀÓ»ó ¿µ¾ç ¼Ö·ç¼ÇÀÇ Áß¿äÇÑ ±â¼ú Çõ½ÅÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ÀÓ»ó ¿µ¾ç ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°è ÀÓ»ó ¿µ¾ç ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è ÀÓ»ó ¿µ¾ç ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è ÀÓ»ó ¿µ¾ç ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº?
  • Äڷγª19°¡ ¼¼°è ÀÓ»ó ¿µ¾ç ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ÀÓ»ó ¿µ¾ç ¼¼°è ½ÃÀåÀÇ Á¦Ç°º° ºÐ·ù´Â?
  • Åõ¿© °æ·Îº° ÀÓ»ó ¿µ¾ç ¼¼°è ½ÃÀå ÇöȲÀº?
  • ÀÓ»ó ¿µ¾ç ¼¼°è ½ÃÀå ³» ÃÖÁ¾ »ç¿ëÀÚº° ºÐ·ù´Â?
  • ÀÓ»ó ¿µ¾ç ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¿ä Áö¿ªÀº?
  • ÀÓ»ó ¿µ¾ç ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ÀÓ»ó ¿µ¾ç ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • À¯¾Æ ¿µ¾ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ºñ°æ±¸ ¿µ¾ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • °æÀå ¿µ¾ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

  • °æ±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • °æÀå
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ºñ°æ±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

  • Á¾¾çÇÐ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿µ¾ç ºÒ·®
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ´ë»çÁúȯ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼ÒÈ­±âÁúȯ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ½Å°æÁúȯ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼Ò¾Æ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼ºÀÎ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ³ëÀÎ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ij³ª´Ù
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÀϺ»
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Àεµ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Çѱ¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • È£ÁÖ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Àεµ³×½Ã¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • À¯·´
    • µ¶ÀÏ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÇÁ¶û½º
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ¿µ±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÀÌÅ»¸®¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ½ºÆäÀÎ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ·¯½Ã¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ¸ß½ÃÄÚ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abbott Laboratories
    • B. Braun Melsungen AG
    • BASF SE
    • Baxter International Inc.
    • Danone S.A.
    • Fresenius SE & Co. KGaA
    • Grifols S.A.
    • Koninklijke DSM N.V.
    • Meiji Holdings Co. Ltd.
    • Nestle S.A.
    • Perrigo Company plc
    • Reckitt Benckiser Group PLC
LSH 24.04.16

The global clinical nutrition market size reached US$ 51.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 101.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.

Clinical nutrition refers to a specialized field of nutrition science that focuses on disease management by adopting medical nutrition therapies. It also includes the diagnosis and prevention of nutritional and metabolic conditions associated with chronic disorders that occur due to the lack of essential nutrients. Some of the commonly available types of clinical nutrition include infant nutrition, enteral nutrition, and parenteral nutrition. Clinical nutrition offers numerous benefits in reducing the consequences of malnutrition, enhancing the response to disease treatment, boosting immunity levels, enhancing ingestion abilities, etc.

Clinical Nutrition Market Trends:

The rising prevalence of metabolic disorders that increase the risk of obesity, high blood pressure, abnormal cholesterol levels, etc., is primarily driving the global clinical nutrition market. Moreover, the expanding geriatric population, who are more prone to chronic gastrointestinal ailments, is also propelling the demand for clinical nutrition in the home healthcare model. Besides this, elevating number of preterm births coupled with the inflating need for clinical nutrition in the pediatric medicine segment is further augmenting the market growth. Additionally, continuous upgradation of healthcare infrastructures and the introduction of government awareness programs regarding the easy accessibility to clinical nutrition procedures for disease management are acting as significant growth-inducing factors. Apart from this, in the COVID-19 pandemic, the demand for immunity-boosting alternatives, including clinical nutrition, has significantly increased to prevent the risk of coronavirus infection. The infection results in severe lack of appetite, anosmia dysgeusia, diarrhea, etc., which can lead to disease-related malnutrition. Clinical nutrition aid in treating acute malnutrition and protein deficiency along with improving immune defenses in COVID-19 patients. Moreover, significant innovations in clinical nutrition solutions, including lipid emulsions optimization, and the introduction of oral clinical nutrition formula in liquid form, are expected to drive the global clinical nutrition market over the forecasted period.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global clinical nutrition market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, route of administration, application and end user.

Breakup by Product:

Infant Nutrition

Parental Nutrition

Enteral Nutrition

Breakup by Route of Administration:

Oral

Enteral

Parenteral

Breakup by Application:

Cancer

Malnutrition

Metabolic Disorders

Gastrointestinal Disorders

Neurological Disorders

Others

Breakup by End User:

Pediatric

Adults

Geriatric

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, BASF SE, Baxter International Inc., Danone S.A., Fresenius SE & Co. KGaA, Grifols S.A., Koninklijke DSM N.V., Meiji Holdings Co. Ltd., Nestle S.A., Perrigo Company plc and Reckitt Benckiser Group PLC.

Key Questions Answered in This Report

  • 1. What was the size of the global clinical nutrition market in 2023?
  • 2. What is the expected growth rate of the global clinical nutrition market during 2024-2032?
  • 3. What are the key factors driving the global clinical nutrition market?
  • 4. What has been the impact of COVID-19 on the global clinical nutrition market?
  • 5. What is the breakup of the global clinical nutrition market based on the product?
  • 6. What is the breakup of the global clinical nutrition market based on the route of administration?
  • 7. What is the breakup of the global clinical nutrition market based on the end user?
  • 8. What are the key regions in the global clinical nutrition market?
  • 9. Who are the key players/companies in the global clinical nutrition market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Clinical Nutrition Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Infant Nutrition
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parental Nutrition
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Enteral Nutrition
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Enteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Parenteral
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Malnutrition
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Metabolic Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Gastrointestinal Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Neurological Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatric
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Geriatric
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 B. Braun Melsungen AG
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 BASF SE
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Baxter International Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Danone S.A.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Fresenius SE & Co. KGaA
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Grifols S.A.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Koninklijke DSM N.V.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Meiji Holdings Co. Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Nestle S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Perrigo Company plc
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Reckitt Benckiser Group PLC
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦